Broad genomic profiling, targeted therapy receipt, and overall survival among patients with metastatic non-squamous non-small cell lung cancer.
51 Background: Broad genomic profiling (BGP) is recommended for all patients with metastatic non-squamous NSCLC to guide targeted therapy (TT) selection. As actionable alterations and matched therapies continue to expand, BGP may identify a broader group of patients eligible for TT and consequently improve pati...